The Size of the Europe Polymerase Chain Reaction Market is valued at USD 2.30 billion in 2022 and is expected to grow at a CAGR of 6.40%, reaching USD 3.13 billion by 2027 during the forecast period 2022 to 2027.
The increased prevalence of different infectious diseases and genetic disorders is one of the key factors driving the market's rise. The sector is also fueled by the growing senior population in Europe, which is more prone to chronic medical conditions.
One of the most important factors is that the medicines are designed to deliver custom-made remedies identified and produced using PCR technology. In addition, the increasing use of clinical diagnostics and extensive research & development (R & R&D) activities in biotechnology are estimated to propel the market forward.
Prenatal genetic testing procedures, rising demand for advanced diagnostic techniques, and an increasing number of CROs, forensic, and research laboratories are driving the Polymerase Chain Reaction (PCR) market; Automation, real-time quantification, precision, accuracy, and sensitivity are among the features that they offer.
Another important factor is that the increased rate of automation, combined with the ability to process a more significant number of samples, is likely to boost demand for molecular diagnostics reagents and consumables, propelling the market forward.
The pandemic's spread has prompted the widespread adoption of PCR technologies for precise infection testing and early detection. PCR devices also help to reduce the risk of contamination and human error during the entire process.
Europe holds the second-largest Polymerase Chain Reaction market share, accounting for 37.8 percent of total revenue in 2020. Favorable government efforts and flexible regulatory rules fuel market expansion.
PCR is a polymerase chain reaction, a molecular diagnostic procedure for making multiple copies of DNA. To make a million copies of DNA sequencing properly, a PCR machine is used to regulate the temperature of the sample is an efficient and pre-programmed technique.
Countries such as Germany and U.K. have launched a new entrant diagnostic system to suit the growing demand for PCR systems in the region.
This research report on the Europe Polymerase Chain Reaction Market has been segmented and sub-segmented into the following categories.
By Type of Application:
Geographically, the Europe polymerase chain reaction market is expected to be driven by the rising adoption of PCR for food safety, infection detection, and food-borne pathogens and toxicogenic fungi. In addition, species identification has become increasingly important for some applications like meat species identification.
The U.K. polymerase chain reaction market is predicted to dominate the market in the European region due to advances in healthcare infrastructure, increased patient awareness, and significant unmet patient demands; the market is expected to increase. In addition, the pandemic has put a substantial burden on qPCR, endpoint PCR, & dPCR diagnostics in this region due to the high incidence and highly inhabited areas.
The German polymerase chain reaction market is estimated to grow at a decent CAGR. Another essential feature is that the technique can identify and culture disease-causing microbes, which can help detect tuberculosis, AIDS, infections, and Lyme disease. As a result, it has numerous applications in life science domains like genetics, biotechnology, molecular biology, drug development, and clinical diagnostics.
KEY MARKET PLAYERS
Prominent Companies dominating the Europe Polymerase Chain Reaction Market Profiled in the Report are Beckman Coulter, Becton, Dickinson, and Company, Promega, Fluidigm, PerkinElmer, bioMérieux, GE, Harvard Bioscience, Maxim Biotech., Kapa Biosystems, RainDance Technologies, and Siemens Healthcare, Cepheid, Clontech Laboratories, Eppendorf.,
Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2000
Call us on: +1 888 702 9696 (U.S Toll Free)
Write to us: firstname.lastname@example.org